Wells Fargo’s Context Therapeutics CNTX Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
$8.5K Sell
28,312
-56,669
-67% -$28K ﹤0.01% 6155
2026
Q2
$47.1K Buy
+84,981
New +$172K ﹤0.01% 5730
2024
Q2
– Sell
-116
Closed -$160 – 6993
2024
Q1
$160 Buy
116
+2
+2% +$2 ﹤0.01% 6547
2023
Q4
$129 Buy
114
+6
+6% +$6 ﹤0.01% 6706
2023
Q3
$163 Buy
108
+1
+0.9% +$1 ﹤0.01% 6634
2023
Q2
$171 Buy
107
+4
+4% +$3 ﹤0.01% 6744
2023
Q1
$58 Buy
103
+2
+2% +$2 ﹤0.01% 7068
2022
Q4
$66 Buy
101
+2
+2% +$2 ﹤0.01% 6916
2022
Q3
$0 Buy
99
+30
+43% – ﹤0.01% 6733
2022
Q2
$0 Buy
69
+5
+8% – ﹤0.01% 6873
2022
Q1
$0 Buy
64
+31
+94% – ﹤0.01% 7138
2021
Q4
$0 Hold
33
– – ﹤0.01% 7258

Other funds holding CNTX

Wells Fargo's CNTX Position: Q3 2026 in Review

Wells Fargo reduced its Context Therapeutics (CNTX) stake by 67% in Q3 2026, selling an estimated $28K and leaving 28,312 shares worth $8.5K. The position accounts for ﹤0.01% of the portfolio, ranked #6155.

Wells Fargo first reported a position in CNTX in Q4 2021 and has held it in 12 quarters since. The position peaked at $47.1K in Q2 2026. 87 funds tracked by Wall St. Rank hold CNTX as of Q3 2026.

  • Wells Fargo held 28,312 shares of Context Therapeutics worth $8.5K as of Q3 2026.
  • Wells Fargo sold 56,669 Context Therapeutics shares in Q3 2026, an estimated $28K.
  • Context Therapeutics made up ﹤0.01% of Wells Fargo's portfolio in Q3 2026, its #6155 holding.
  • Wells Fargo first reported a position in Context Therapeutics in Q4 2021 and has held it in 12 quarters since.
  • Wells Fargo's Context Therapeutics position peaked at $47.1K in Q2 2026.
  • 87 funds tracked by Wall St. Rank held Context Therapeutics as of Q3 2026.

Based on Wells Fargo's 13F filing for Q3 2026, filed 16 Nov 2026.